Silexion Therapeutics

Company Overview

Snapshot

Founded in November 2008, Silexion Therapeutics is a public company with 11–50 employees, co-founded by Amotz Shemi, PhD. The company has raised $27.65 million across six funding rounds. In August 2024, Silexion Therapeutics went public on NASDAQ following a SPAC event with Moringa Acquisition Corp.

Business overview

Silexion Therapeutics is a developmental stage company focused on creating innovative treatments for pancreatic cancer within the Health Tech & Life Sciences sector. The company leverages RNA interference technology to develop RNA-based therapeutics that silence specific genes involved in cancer growth and metastasis. Its core product, LODERTM, has shown positive efficacy results in phase 2 clinical trials, and Silexion is enhancing this product to improve clinical efficacy against pancreatic cancer. The company operates in the Pharmaceuticals, Drugs Discovery & Development, and Biologicals (Genes) categories, serving the healthcare and life sciences industries.

Strategic signal

Silexion Therapeutics is demonstrating significant progress in its clinical development pipeline, particularly with its SIL204 program. In May 2026, the company announced positive preliminary immunotherapy findings for SIL204 in KRAS-Driven Pancreatic Cancer and initiated GMP clinical supply manufacturing, alongside receiving approval for a Phase 2/3 trial from. This indicates a strong forward trajectory in advancing its next-generation RNA silencing therapy towards later-stage clinical trials and potential market entry, signaling to investors a maturing product pipeline and strategic execution in a high-need therapeutic area.

Company Intelligence Q&A

When did Silexion Therapeutics go public?

Silexion Therapeutics went public on NASDAQ in August 2024, following a SPAC event with Moringa Acquisition Corp.

What is the latest development regarding Silexion Therapeutics' SIL204 program?

In May 2026, Silexion Therapeutics announced positive preliminary immunotherapy findings for SIL204 in KRAS-Driven Pancreatic Cancer. Concurrently, the company initiated GMP clinical supply manufacturing of SIL204 and received approval for a Phase 2/3 trial from Tel Aviv Sourasky Medical Center.

What were Silexion Therapeutics' financial results for the first quarter of 2026?

Silexion Therapeutics reported its First Quarter 2026 Financial Results and provided a business update in May 2026.

What was the outcome of the public offering in September 2025?

In September 2025, Silexion Therapeutics announced the pricing of a $6.0 million public offering.

What was the result of the toxicology studies for SIL204?

In November 2025, Silexion Therapeutics successfully completed toxicology studies for SIL204, its next-generation RNA silencing therapy, ahead of its Phase 2/3 clinical trial in pancreatic cancer.